Alcresta Therapeutics

Alcresta Therapeutics is a commercial-stage biotech company addressing a critical unmet need in enteral nutrition for patients with rare diseases. Its core technology is the RELiZORB cartridge, which contains immobilized lipase (iLipase) to break down fats in tube feeding formulas, mimicking pancreatic function. The company has achieved FDA clearance for expanded use in neonates and infants and is generating real-world evidence to support its product. Led by an experienced management team, Alcresta is positioned in the niche but essential markets of metabolic and rare diseases with a specialized drug delivery platform.

iLipase® immobilized lipase microbead/enzyme technology for in-line digestion of fats in enteral feeding formulas.

RELiZORB is first-to-market as the only FDA-cleared enzyme product for enteral feeding, creating a unique niche. Potential competitors include off-label use of oral pancreatic enzyme supplements or future novel devices from larger medical nutrition or gastroenterology-focused companies.